Navigation Links
Moussa B.H. Youdim wins the 2010 ECNP Lifetime Achievement Award
Date:9/2/2010

The European College of Neuropsychopharmacology (ECNP) is pleased to announce Moussa B. H. Youdim as the recipient of the 2010 ECNP Lifetime Achievement Award in recognition of his innovative and lasting contribution to the area of neurodegenerative diseases and neuropsychiatric drug development. The ECNP Lifetime Achievement Award is presented biennially and recognises significant and lasting impact on the field of neuropsychopharmacology. The award is accompanied by a prize of 20,000.

Moussa B. H. Youdim, born in 1940 in Teheran, is Finkelstein Professor of Life Sciences and at Rappaport Faculty of Medicine at the Technion-Israel Institute of Technology, Haifa, Israel. He is also founder and Director of the Eve Topf and U.S. National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Teaching, an independent extension of the Department of Pharmacology dedicated to advancing the understanding of neuropsychiatric disorders.

"With regard to current treatment standards based on symptom control, innovative neuroprotective therapies are needed in the common neurodegenerative disorders," he emphasised on the occasion of the 23rd ECNP Congress in Amsterdam, the Netherlands. Moussa Youdim has gained a worldwide reputation for his work in addressing this need in Parkinson's disease and Alzheimer's disease over nearly 50 years of highly productive activity.

He is especially known for his key role in establishing the importance of the monoamine oxidase enzymes, which are central to the metabolism of neurotransmitters such as dopamine, noradrenaline and serotonin, and the connection between these enzymes and abnormal brain iron metabolism. He has also pursued this research into the clinic, with the development of novel treatments for neurodegenerative diseases. "A current challenge for drug discovery designed for complex brain disorders such as Parkinson's or Alzheimer's disease is to look for multimodal drugs with a disease modifying effect," said Youdim.

Presenting the award at the 23rd ECNP Congress in Amsterdam, the chairman of the ECNP Award Jury 2010, Tomas Hkfelt of the Karolinska Institute in Stockholm, highlighted Youdim's scientific discoveries and their public health implications. "Demographic changes in Europe are making Parkinson's and Alzheimer's an increasing public health concern. Moussa Youdim's contribution to our understanding and better treatment of these conditions has been lasting and significant. We congratulate him on this well-deserved award."


'/>"/>

Contact: Sonja Mak
s.mak@update.europe.at
431-405-5734
European College of Neuropsychopharmacology
Source:Eurekalert

Related biology news :

1. Study shows genes role in developing and maintaining cells key for a lifetime of memories
2. University of Washington professors lifetime efforts receive international recognition
3. Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award
4. Dian Donnai receives lifetime award in genetics from March of Dimes
5. Maverick green economist gets lifetime achievement award
6. Exposure to secondhand cigarette smoke over a lifetime increased breast cancer risk later in life
7. Roberta A. Pagon receives lifetime award in genetics from March of Dimes
8. Carnegies Donald Brown receives lifetime achievement award from Society for Developmental Biology
9. A low dose of caffeine when pregnant may damage the heart of offspring for a lifetime
10. IOF Medal of Achievement for outstanding scientific contributions awarded to John A. Kanis
11. To close achievement gap, US must address major health risks for urban minority youth, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special Counsel to ... of Identity Strategy Partners, LLP, today releases the following ... Protecting the Nation From Foreign Terrorist Entry Into the ... Trump,s ,Travel Ban, Executive Order gains more notoriety and ... ban, it is important that our national discourse regain ...
(Date:2/8/2017)... -- Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion ... at a compound annual growth rate (CAGR) of 24.0% through ... markets for synthetic biology. - Analyses of global market trends, ... compound annual growth rates (CAGRs) through 2021. - Coverage of ...
(Date:2/7/2017)... LONG BEACH, New York , February 7, 2017 ... formerly known as ID Global Solutions Corporation [OTC: IDGS], ... identification, identity management and electronic transaction processing services, is ... a reorganization of the Company. Effective January ... Chairman of the Board of Directors, CEO and President. ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... 2017 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ... and commercialization of innovative therapies for the treatment ... Food and Drug Administration (FDA) has accepted the ... for DSUVIA™ (formerly ARX-04) (sufentanil sublingual tablet, 30 ... acute pain in a medically supervised setting. The ...
(Date:2/27/2017)... FRANCISCO , Feb. 27, 2017 Fluxion ... Spain has been appointed as a ... System. The IsoFlux system will be used in Genetracer ... relevant to lung and colon cancer, with plans to ... The laboratory is utilizing Fluxion,s IsoFlux System to isolate, ...
(Date:2/26/2017)... ... February 26, 2017 , ... Rob Lowe is a well recognized television personality, ... "Informed," focuses on issues that are important to the American public and important to ... has been a hot topic around the world for a few years. , The ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Delpor, Inc. ... $224K grant from the National Institute of Mental Health (NIMH) for the further advancement ... Delpor’s PROZOR technology and is expected to deliver therapeutic levels of olanzapine ...
Breaking Biology Technology: